Bilateral Chylothorax After 13 Years of Dasatinib Therapy in a Patient With Chronic Myeloid Leukaemia: A Case Report. [PDF]
Watanabe R +6 more
europepmc +1 more source
Synergistic Anti-Tumor Activity of LRPPRC Inhibition and Dasatinib Through Dual Oxidative Phosphorylation Disruption. [PDF]
Chen J +7 more
europepmc +1 more source
Dasatinib Associated Pleural Complications- A Case Series. [PDF]
Vazhoor V +4 more
europepmc +1 more source
Identifying ICAM-1 as a Therapeutic Target for Cytokine Storm in Human Macrophages Through Integrative Bioinformatics Approaches. [PDF]
Chen S, Wu D, Zheng Z, Luo Y, Zhang L.
europepmc +1 more source
Dasatinib boosts γδ T cell expansion and memory phenotypes with enhanced antitumor immunity. [PDF]
Lin JR +9 more
europepmc +1 more source
Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study. [PDF]
Cheng F +5 more
europepmc +1 more source
Development and Validation of a Robust RP-HPLC Method for Quantifying Dasatinib in Self-Microemulsifying Drug Delivery Systems. [PDF]
Kokare NV +12 more
europepmc +1 more source
Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design. [PDF]
Jambon-Barbara C +8 more
europepmc +1 more source
Unmasking Cytomegalovirus Colitis: A Case of Haemorrhagic Colitis in a Patient with Chronic Myeloid Leukaemia on Dasatinib. [PDF]
Tole MC +6 more
europepmc +1 more source
Construction of a Prognostic Model and Subgroup Characteristics Related to Hypoxia-Immune Evasion in T Cells of Hepatocellular Carcinoma Based on Single-Cell and Bulk RNA Analysis. [PDF]
Ma X, Ying L, Xiang X.
europepmc +1 more source

